FENOVERINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C26H25N3O3S
Molecular Weight	459.56
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C(CN1CCN(CC2=CC=C3OCOC3=C2)CC1)N4C5=CC=CC=C5SC6=C4C=CC=C6

InChI

InChIKey=UBAJTZKNDCEGKL-UHFFFAOYSA-N

InChI=1S/C26H25N3O3S/c30-26(29-20-5-1-3-7-24(20)33-25-8-4-2-6-21(25)29)17-28-13-11-27(12-14-28)16-19-9-10-22-23(15-19)32-18-31-22/h1-10,15H,11-14,16-18H2

HIDE SMILES / InChI

Molecular Formula	C26H25N3O3S
Molecular Weight	459.56
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24262593 | https://www.ncbi.nlm.nih.gov/pubmed/16524578 | https://www.ncbi.nlm.nih.gov/pubmed/18058319

Fenoverine is a potent musculotropic, the anti-spasmodic agent that restores smooth muscle motility and relieves the distressing symptoms associated with irritable bowel syndrome (IBS) and primary dysmenorrhea. Fenoverine is a non-anticholinergic phenothiazine derivative that may also inhibit calcium channel currents. Fenoverine primarily affects the gastrointestinal tract, bile duct, and female genital organs. Fenoverine has been repeatedly implicated in the occurrence of rhabdomyolysis, a potentially fatal adverse effect, in France. Thes drug has been therefore unavailable in France since December 1995 but commonly used in the treatment of gastrointestinal spasmodic disorders in Taiwan.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
calcium ion transmembrane transport 3 Target ID: GO:0070588 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3113828	Modulator 828
calcium channel activity 11 Target ID: GO:0005262 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1786520	Blocker 537		7.5 µM [IC50]

PubMed

Title	Date	PubMed
Rhabdomyolysis induced by fenoverine: a case report and literature review.	2005 Sep	16252617
Fenoverine vs. mefenamic acid in the treatment of primary dysmenorrhea.	2006 Apr	16524578
Formulation and evaluation of rapidly disintegrating fenoverine tablets: effect of superdisintegrants.	2007 Nov	18058319
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443
Formulation and evaluation of multiple tablets as a biphasic gastroretentive floating drug delivery system for fenoverine.	2010 Mar	20228043
In vitro evaluation of domperidone mouth dissolving tablets.	2010 Nov	21969764

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:38:25 UTC 2023` Edited by `admin` on `Sat Dec 16 17:38:25 UTC 2023`
Record UNII	N274ZQ6PZJ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FENOVERINE

Official Name

English

FENOVERINE [MI]

Common Name

English

10-((4-PIPERONYL-1-PIPERAZINYL)ACETYL)PHENOTHIAZINE

Systematic Name

English

Fenoverine [WHO-DD]

Common Name

English

fenoverine [INN]

Common Name

English

FENOVERINE [MART.]

Common Name

English

10-((4-(1,3-BENZODIOXOL-5-YLMETHYL)-1-PIPERAZINYL)ACETYL)-10H-PHENOTHIAZINE

Systematic Name

English

SPASMOPRIV

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29698